Which company develops and produces Assimini?

Asciminib (scemblix/asciminib) is developed and produced by Novartis Pharmaceuticals. It is an oral small molecule drug. Aceminibis indicated for the treatment of the following adult patients: Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) is in the chronic phase (CP) and has received two or more tyrosine kinase inhibitors (TKIs) treatment as well as T315I mutation chronic myelogenous leukemia of Ph+chronic myelogenous leukemia.

The apparent volume of distribution of aceminib at steady state is 151 L (135%). Asiminilis the major circulating component in plasma (93% of the administered dose). Aximini is 97%bound to human plasma proteins in the test tube. The overall apparent clearance of 40mg twice daily and 80mg once daily aceminib was 6.7L/ hours (48%), the total apparent clearance of 200mg twice daily was 4.1 liters/ hours (38%). 40mg twice daily and 80mg once-daily aceminib has a terminal elimination half-life of 5.5 hours (38%), 200mg twice daily has a terminal elimination half-life of 9.0 hours (33%). Asiminibis metabolized by CYP3A4-mediated oxidation, UGT2B7, and UGT2B17-mediated glucuronidation. Oral single dose80 mgRadiolabeledaceminibLater, 80% (57%unchanged) and 11% (2.5%unchanged) of the aceminib dose were recovered in the feces and urine of healthy subjects, respectively. Aximinilis cleared by bile secretion via breast cancer-resistant protein (BCRP). The retail price of Lucius Pharmaceuticals in Laos40mg60tablets4more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.